Previously, bifunctional peptide inhibitors (BPI) with a single antigenic peptide have been shown to suppress experimental autoimmune encephalomyelitis (EAE) in an antigen-specific manner. In this study, a multivalent BPI (MVB MOG/PLP ) with two antigenic peptides derived from myelin oligodendrocyte glycoprotein ) and myelin proteolipid protein (PLP 139-151 ) was evaluated in suppressing MOG 38-50 -and PLP 139-151 -induced EAE. MVB MOG/PLP significantly suppressed both models of EAE even when there was some evidence of epitope spreading in the MOG 38-50 -induced EAE model. In addition, MVB MOG/PLP was found to be more effective than PLP-BPI and MOG-BPI in suppressing MOG 38-50 -induced EAE. Thus, the development of MVB molecules with broader antigenic targets can lead to suppression of epitope spreading in EAE.
Introduction
Multiple sclerosis (MS) is an immune-mediated neurodegenerative disease of the central nervous system (CNS). The pathogenesis of MS has not been fully elucidated; however, it is categorized as a CD4 + T cell-mediated autoimmune disease (Zhang et al., 1994; Bielekova et al., 1999) . It is thought that there is a breakdown in the recognition of self versus non-self antigens, and that the immune system starts recognizing protein components of the myelin sheath as antigens. Major immunodominant proteins of the myelin sheath are myelin proteolipid protein (PLP), myelin oligodendrocyte glycoprotein (MOG), and myelin basic protein (MBP). During disease, T cells can recognize epitopes of these proteins and initiate an inflammatory immune response toward them, leading to tissue damage. The debris from the broken down tissue leads to epitope spreading, thus resulting in new tissue components becoming antigenic (Vanderlugt and Miller, 1996) . An animal model known as experimental autoimmune encephalomyelitis (EAE) is often used to study MS. This model mimics some of the pathological features of MS such as CNS inflammation, lesion formation, blood-brain barrier (BBB) breakdown, and the presence of myelinspecific CD4 + T cells (Voskuhl et al., 1993; Lassmann, 2001 ). In addition, the animal model can be used to study the epitope spreading process (Tuohy and Kinkel, 2000) . Unlike MS, however, EAE has an initiating antigen that can be controlled by injection of the encephalitogenic peptide in the presence of complete Freund's adjuvant (CFA). This is a powerful tool because therapies can be developed to specifically suppress the immune response to these antigens. Antigen-specific immunotherapy has become widely investigated recently with the aim of inducing tolerance to specific antigens; therefore, it attenuates the inflammatory response. Previously in our laboratory, bifunctional peptide inhibitors (BPI) composed of antigenic peptides conjugated to adhesion peptides have been developed and have successfully suppressed EAE (Kobayashi et al., 2007; Kobayashi et al., 2008; Ridwan et al., 2010; Zhao et al., 2010; Manikwar et al., 2012) . BPI molecules contain a specific antigen (i.e., PLP) and have been shown to suppress EAE induced by a specific antigen (i.e., PLP). Therefore, they will not be useful for suppressing EAE generated by a different antigen (i.e., MOG or MBP). In addition, antigen-specific modulation may not solve the problem of epitope spreading when the disease is in its late stage. Therefore, a new kind of BPI molecule known as multivalent BPI (MVB) has been designed with more than one antigen. The goal is that the MVB molecule will modulate the immune response to suppress the disease regardless of the inciting antigen, thus solving the problem of epitope spreading and making this strategy more applicable for translation into a MS therapy. In EAE and MS, the activation of inflammatory CD4 + T cells is mediated by two signals that are delivered from antigen-presenting cells (APC) to T cells (Grakoui et al., 1999; Tseng and Dustin, 2002) . The first signal (Signal 1) is the antigen presentation by the major histocompatibility complex class-II (MHC-II) molecule, which is recognized by the T-cell receptor (TCR). The second signal (Signal 2) is made up of costimulatory and adhesion molecules on both APC and T cells. After the molecular pair interactions form both signals, signal
